clinical trial · NCT06321523
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Pfizer·—·completed·n = 13
Transthyretin Amyloid CardiomyopathyTafamidis 61 milligrams
brief summary
The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM). This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.
started
Mar 19, 2024
primary completion
Oct 13, 2025
completion
Oct 13, 2025
last updated
Nov 20, 2025
official title
Clinical Benefit of Tafamidis 61mg for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Patients in Korean Population in the Real-world Setting, Multicenter, Non-interventional Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol